+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarepta Therapeutics - logo

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

From
From
From
From
From
From
From
From
From
From
Niemann-Pick Type C Disease - Pipeline Insight, 2021 - Product Thumbnail Image

Niemann-Pick Type C Disease - Pipeline Insight, 2021

  • Clinical Trials
  • September 2021
  • 60 pages
From
Pompe Disease - Pipeline Review, H2 2020 - Product Thumbnail Image

Pompe Disease - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 104 pages
From
Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2020 - Product Thumbnail Image

Spinal Muscular Atrophy (SMA) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 164 pages
From
From
Survival Motor Neuron Protein - Pipeline Review, H1 2020 - Product Thumbnail Image

Survival Motor Neuron Protein - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 92 pages
From
Multiple Sclerosis - Pipeline Review, H1 2020 - Product Thumbnail Image

Multiple Sclerosis - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 1114 pages
From
From
Loading Indicator
adroll